Breaking Down Cytosorbents Corporation (CTSO) Financial Health: Key Insights for Investors

Are you keeping a close watch on Cytosorbents Corporation (CTSO) and wondering about its financial stability? Did you know that in 2024, CytoSorbents achieved a 15% increase in CytoSorb sales, reaching $35.6 million, with a product gross margin of 71%? But how does this translate into overall financial health? What are the key factors driving their performance, and what challenges might they face? Dive in to uncover critical insights into CytoSorbents' financial standing, giving you a clear picture of where they stand and what could be on the horizon.

Cytosorbents Corporation (CTSO) Revenue Analysis

Cytosorbents Corporation's financial health can be better understood through a detailed analysis of its revenue streams. Examining where the company's revenue comes from, how it has grown, and the different segments that contribute to the total can provide key insights for investors.

A breakdown of Cytosorbents Corporation’s primary revenue sources reveals that the company generates income primarily through the sale of its flagship product, CytoSorb, and related products used in critical care settings. Geographically, revenue is derived from sales in various regions, including North America, Europe, and the rest of the world. Understanding the contribution from each of these sources is vital for assessing the company’s overall financial stability and growth potential. Additional information about the company's mission can be found at: Mission Statement, Vision, & Core Values of Cytosorbents Corporation (CTSO).

Analyzing the year-over-year revenue growth rate provides a view of Cytosorbents Corporation's performance over time. Monitoring historical trends and calculating the percentage increase or decrease in revenue each year can indicate whether the company is expanding, stagnating, or contracting. This information is helpful for forecasting future revenue and assessing the company's growth trajectory.

To illustrate, consider a hypothetical scenario based on available information and focusing on 2024 fiscal year data:

Let's assume Cytosorbents reported total revenue of $40 million for the fiscal year 2023. For the fiscal year 2024, the company reports total revenue of $45 million. This would represent a year-over-year revenue growth rate of 12.5%.

The calculation is as follows:

((Revenue in 2024 - Revenue in 2023) / Revenue in 2023) 100

(($45 million - $40 million) / $40 million) 100 = 12.5%

Understanding the contribution of different business segments to Cytosorbents Corporation’s overall revenue is crucial. Revenue can be segmented by product type (e.g., CytoSorb product sales, accessories) or by geographic region (e.g., North America, Europe, Asia-Pacific). Analyzing these segments helps identify which areas are driving growth and which may need improvement.

Here's an example of how different segments might contribute to the overall revenue:

• CytoSorb Product Sales: 70% of total revenue
• Accessories and Consumables: 20% of total revenue
• Service and Other Revenue: 10% of total revenue

Significant changes in Cytosorbents Corporation’s revenue streams should be closely examined. These changes could result from various factors, such as:

• New product launches
• Changes in market demand
• Regulatory approvals or changes
• Entry into new geographic markets
• Changes in pricing strategies

For instance, if Cytosorbents Corporation received FDA approval for a new indication of CytoSorb in the United States, this could significantly increase sales in the North American market. Conversely, if a major distributor in Europe terminated their agreement, this could negatively impact revenue in that region.

To summarize, a thorough analysis of Cytosorbents Corporation’s revenue streams involves understanding the sources of revenue, tracking year-over-year growth, assessing the contribution of different business segments, and monitoring any significant changes that could impact future revenue. This detailed approach will equip investors with the insights needed to make informed decisions about the company’s financial health and growth prospects.

Cytosorbents Corporation (CTSO) Profitability Metrics

Analyzing Cytosorbents Corporation's profitability involves scrutinizing its gross profit, operating profit, and net profit margins to understand its financial health and operational efficiency. Examining these metrics over time provides insights into the company's ability to generate profit from its revenue, manage its expenses, and ultimately deliver value to its investors.

As of the fiscal year 2024, Cytosorbents Corporation's financial performance reveals the following:

• Gross Profit Margin: Monitoring gross profit margin trends helps evaluate the efficiency of production and pricing strategies.
• Operating Profit Margin: Examining operating profit margins indicates how well Cytosorbents Corporation manages its operational expenses.
• Net Profit Margin: The net profit margin reflects the percentage of revenue remaining after all expenses, including taxes and interest, have been deducted.

To provide a clearer picture, here’s a summary of Cytosorbents Corporation’s key profitability metrics based on the latest available data:

In 2024, Cytosorbents reported a gross profit of $24.5 million. However, the company faced significant operating expenses, totaling $43.4 million. This resulted in a net loss of $20.7 million for the year. These figures highlight the challenges Cytosorbents faces in achieving overall profitability despite generating gross profit.

A comparison of profitability ratios with industry averages can highlight areas where Cytosorbents Corporation excels or needs improvement. This benchmark helps investors understand whether the company's profitability is in line with industry standards or if there are significant deviations.

Analysis of operational efficiency, such as cost management and gross margin trends, is crucial for assessing Cytosorbents Corporation's ability to control expenses and improve profitability. Effective cost management and positive gross margin trends can contribute to enhanced financial performance and long-term sustainability.

Explore more about Cytosorbents Corporation and its investors: Exploring Cytosorbents Corporation (CTSO) Investor Profile: Who’s Buying and Why?

Cytosorbents Corporation (CTSO) Debt vs. Equity Structure

Understanding how Cytosorbents Corporation (CTSO) manages its debt and equity is crucial for investors. It provides insights into the company's financial stability and growth strategies. This analysis covers the company's debt levels, its debt-to-equity ratio, and how it balances debt and equity financing.

As of the fiscal year 2024, Cytosorbents Corporation's debt structure includes both short-term and long-term obligations. While specific figures for 2024 are not available, examining the trends from previous years can provide a perspective. It's essential to refer to the company's latest financial statements for the most accurate data. Typically, short-term debt consists of obligations due within a year, while long-term debt includes bonds and other financing arrangements extending beyond one year.

The debt-to-equity ratio is a key metric for evaluating Cytosorbents Corporation's financial leverage. This ratio compares the total debt to the total equity, indicating the extent to which the company is using borrowed money to finance its assets. A high ratio suggests a more aggressive financing approach, which can amplify both profits and losses. A lower ratio typically indicates a more conservative approach. It is important to compare Cytosorbents Corporation's ratio to industry standards to gauge whether it is in line with its peers.

While specific details on recent debt issuances, credit ratings, or refinancing activities for 2024 are not available, such events can significantly impact the company’s financial health. Any new debt issuances would increase the company's liabilities, while a credit rating upgrade could lower borrowing costs. Refinancing activities might be undertaken to take advantage of lower interest rates or to extend the maturity of existing debt.

Balancing debt and equity is a strategic decision for Cytosorbents Corporation. Debt financing can provide capital for growth initiatives without diluting ownership. However, it also introduces fixed interest expenses and increases financial risk. Equity funding, on the other hand, strengthens the balance sheet and provides flexibility but can dilute existing shareholders' stakes. The company's approach to this balance reflects its growth strategy and risk tolerance.

Here are some factors influencing Cytosorbents Corporation's debt vs. equity balance:

• Market Conditions: Prevailing interest rates and investor sentiment can impact the attractiveness of debt versus equity financing.
• Growth Opportunities: Ambitious growth plans may require significant capital, influencing the choice between debt and equity.
• Financial Performance: Consistent profitability and cash flow can support higher debt levels.
• Shareholder Expectations: The company must consider the impact of its financing decisions on shareholder value and potential dilution.

A detailed look at Cytosorbents Corporation's financial statements, including the balance sheet and cash flow statement, is essential for a thorough understanding of its debt and equity structure. Monitoring these elements over time provides valuable insights into the company's financial management and strategic direction.

For more information on Cytosorbents Corporation, see: Exploring Cytosorbents Corporation (CTSO) Investor Profile: Who’s Buying and Why?

Cytosorbents Corporation (CTSO) Liquidity and Solvency

Assessing Cytosorbents Corporation's (CTSO) liquidity involves examining several key financial metrics and trends. This analysis provides insights into the company's ability to meet its short-term obligations and manage its working capital effectively. Here's a breakdown of CTSO's liquidity position:

Liquidity Ratios:

• Current Ratio: As of December 2024, CTSO's current ratio was approximately 2.20. This indicates that the company has $2.20 of current assets for every $1 of current liabilities.
• Quick Ratio: The quick ratio, which excludes inventory from current assets, was approximately 1.08 as of December 2024. This suggests that CTSO has about $1.08 of readily convertible assets to cover each dollar of current liabilities.

Working Capital Trends:

CTSO's working capital, the difference between current assets and current liabilities, stood at $11.78 million as of December 31, 2024. Monitoring the trend of working capital is crucial to understanding the company's operational efficiency and short-term financial health.

Cash Flow Statements Overview:

An overview of CTSO's cash flow statements reveals the trends in operating, investing, and financing activities. For the three months ended March 31, 2024, operating cash flows related to operating leases amounted to approximately $552,000. It is important to note that as of March 31, 2024, CTSO's cash, cash equivalents, and restricted cash balances were approximately $10.1 million. The company has raised $7.85 million in Q1 2025 through a Rights Offering and warrant exercises, with net proceeds of $7.3 million.

Cash Flow Trends:

Reviewing the cash flow trends, CTSO's free cash flow for Q3 2024 was $0.52 million. For the 2024 fiscal year, CTSO's free cash flow decreased, and operating cash flow was $-0.20 million.

Liquidity Concerns and Strengths:

One potential liquidity concern is highlighted in the SEC filing as of March 31, 2024, where the company's cash, cash equivalents, and restricted cash balances were approximately $10.1 million. This raises substantial doubt about the company's ability to continue as a going concern beyond the next twelve months from the issuance of those financial statements. However, CTSO has taken several steps to address these concerns and bolster its financial position:

• In June 2024, CTSO secured a $20 million term-loan facility with Avenue Capital Group, providing an initial tranche of $15 million.
• The company successfully closed its oversubscribed rights offering, raising $6.25 million in gross proceeds.
• These actions have strengthened the company's balance sheet, with an increase of net liquidity available to the company of approximately $10.8 million, net of related offering fees.

Additional Highlights:

• CTSO expects regulatory decisions for DrugSorb-ATR marketing applications from the FDA and Health Canada in 2025.
• The company projects Q4 2024 product revenue of $9.0-9.2 million, representing 22-25% growth vs Q4 2023.
• Full-year 2024 product revenue is projected to be $35.4-35.6 million, a 14% increase compared to 2023.

For more detailed insights, you can refer to Breaking Down Cytosorbents Corporation (CTSO) Financial Health: Key Insights for Investors.

Cytosorbents Corporation (CTSO) Valuation Analysis

Determining whether Cytosorbents Corporation (CTSO) is overvalued or undervalued requires a multifaceted approach, considering various financial ratios, stock performance, and analyst expectations. Here's an overview of key valuation metrics:

• Access Breaking Down Cytosorbents Corporation (CTSO) Financial Health: Key Insights for Investors for comprehensive insights.

Valuation Ratios:

• Price-to-Earnings (P/E) Ratio: As of April 2025, Cytosorbents' P/E ratio is not applicable (N/A) or negative, reflecting negative earnings. For example, one source indicates a P/E ratio of -3.1. A negative P/E ratio suggests the company is not currently profitable.
• Price-to-Book (P/B) Ratio: The P/B ratio, which compares a company's market capitalization to its book value, is around 5.04 to 5.80. A higher P/B ratio could indicate that the stock is overvalued relative to its assets.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Cytosorbents' EV/EBITDA ratio has fluctuated, with recent data showing -5.5x. The EV/EBITDA ratio has varied significantly over the past five years, peaking at -1.8x in December 2022 and hitting a low of -21.8x in December 2020.

Stock Price Trends:

• Recent Performance: As of April 2025, the current price of CTSO is around $1.03.
• 1-Year Performance: Over the past year, Cytosorbents has shown a 31.71% increase.
• Volatility: CTSO stock is considered 7.13% volatile, with a beta coefficient of 0.42.
• 52-Week Range: The 52-week high is $1.61, and the 52-week low is $0.70.

Dividend Information:

• Dividend Yield: Cytosorbents does not currently pay dividends to its shareholders, resulting in a 0% dividend yield.

Analyst Consensus:

• Ratings: The consensus rating for Cytosorbents stock is 'Buy'.
• Price Targets: Analysts' twelve-month price targets range from $1.00 to $10.00, with an average price target of $4.67.

Additional Considerations:

• Market Capitalization: As of April 2025, Cytosorbents has a market capitalization of approximately $64.38 million.
• Revenue and Earnings: The company's most recent quarterly revenue was $9.20 million, below the estimated $10.25 million. The last quarter earnings per share (EPS) was -$0.03, compared to an estimated -$0.05.

The following table summarizes Cytosorbents' key financial statistics:

Based on analyst ratings, Cytosorbents Corp's 12-month average price target is $1.00. Cytosorbents Corp has 3.09% upside potential, based on the analysts' average price target. Cytosorbents Corp has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

In the current month, CTSO has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings.

Keep in mind that these metrics offer a snapshot of Cytosorbents Corporation's financial health and valuation. Investment decisions should be based on thorough research, considering both quantitative data and qualitative factors.

Cytosorbents Corporation (CTSO) Risk Factors

Cytosorbents Corporation (CTSO) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market dynamics, requiring a multifaceted approach to mitigation. Understanding these potential pitfalls is crucial for investors assessing the company's long-term viability.

Here's an overview of key risks:

• Industry Competition: The medical device and critical care sectors are intensely competitive. Cytosorbents faces competition from larger, more established companies with greater resources, potentially impacting market share and profitability.
• Regulatory Changes: Medical devices are subject to stringent regulatory requirements. Changes in regulations or delays in approvals can significantly affect Cytosorbents' ability to market and sell its products.
• Market Conditions: Economic downturns or shifts in healthcare spending can reduce demand for Cytosorbents' products, impacting revenue and growth.

Operational, financial, and strategic risks are often highlighted in Cytosorbents Corporation's earnings reports and filings. These include:

• Operational Risks: Manufacturing disruptions, supply chain issues, or product quality problems could lead to delays, increased costs, and damage to the company's reputation.
• Financial Risks: The company's ability to manage its cash flow, secure additional funding, and maintain profitability are critical. Failure to meet these financial goals could jeopardize its operations.
• Strategic Risks: Decisions related to product development, market expansion, and partnerships carry inherent risks. Poor strategic choices can lead to wasted resources and missed opportunities.

Mitigation strategies and plans are essential for addressing these risks. While specific details may vary, common approaches include:

• Diversification: Expanding into new markets or developing new products can reduce reliance on a single product or region.
• Cost Management: Implementing cost-control measures and improving operational efficiency can enhance profitability.
• Strategic Partnerships: Collaborating with other companies can provide access to new technologies, markets, and resources.
• Compliance: Maintaining strict adherence to regulatory requirements and ethical standards is crucial for avoiding legal and reputational risks.

For deeper insights into the company's mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of Cytosorbents Corporation (CTSO).

Cytosorbents Corporation (CTSO) Growth Opportunities

Cytosorbents Corporation (CTSO) faces a dynamic future shaped by product innovation, strategic market expansion, and evolving healthcare needs. Understanding these factors is crucial for assessing the company's growth trajectory.

Key growth drivers for Cytosorbents Corporation (CTSO) include:

• Product Innovations: Continued development and introduction of new products and applications for CytoSorb technology.
• Market Expansion: Increasing penetration into existing markets and expansion into new geographic regions.
• Acquisitions: Strategic acquisitions to broaden the product portfolio and market reach.

Analyzing Cytosorbents Corporation (CTSO)'s competitive advantages provides insights into its ability to capitalize on future growth opportunities:

• Proprietary Technology: CytoSorb's unique blood purification technology offers a competitive edge in the critical care market.
• Clinical Evidence: A growing body of clinical data supporting the efficacy of CytoSorb in various medical conditions.
• Strategic Partnerships: Collaborations with leading medical institutions and industry partners to drive adoption and expand market access.

Future revenue growth for Cytosorbents Corporation (CTSO) hinges on several factors, including the continued adoption of CytoSorb in critical care settings, expansion into new therapeutic areas, and successful execution of strategic initiatives. While specific revenue growth projections and earnings estimates vary depending on the source and assumptions, the overall outlook remains positive, driven by the increasing demand for effective blood purification therapies.

Strategic initiatives and partnerships play a crucial role in Cytosorbents Corporation (CTSO)'s growth strategy. These collaborations can accelerate product development, expand market access, and enhance the company's competitive position. Examples of such initiatives include:

• Distribution Agreements: Partnering with distributors to expand the reach of CytoSorb in key markets.
• Research Collaborations: Collaborating with research institutions to explore new applications for CytoSorb technology.

Here is a table summarizing potential future growth prospects based on various strategic factors:

Explore a detailed analysis of Cytosorbents Corporation (CTSO)'s financial health: Breaking Down Cytosorbents Corporation (CTSO) Financial Health: Key Insights for Investors